Hyloris to Report 2021 Half-Year Results on 4 August 2021
Liège, Belgium – 27 July 2021 –Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that it will host a conference call and audio webcast on Wednesday, 4 August 2021 at 3:00 pm CEST (9:00 am EST) to present its half-year 2021 financial results and to provide a business update. The presentation will be followed by a live Q&A session.
The webcast may be accessed on the Events page of the company’s website or by clicking here. To participate in the Q&A session of the conference call, please dial one of the following numbers, ten minutes prior to the start of the live webcast:
Belgium +32 2 79 338 47
France +33 1 70 700 781
Netherlands + 31 20 795 6614
United Kingdom +44 2071 928 338
United States +1 646 741 3167
Confirmation code 2687826
Following the call, a replay of the webcast will be available on the events page of the Hyloris website.
About Hyloris Pharmaceuticals
Hyloris is a specialty biopharma company focused on innovating, reinventing, and optimising existing medications to address important healthcare needs and deliver relevant improvements for patients, healthcare professionals and payors. Hyloris has built a broad, patented portfolio of 13 reformulated and repurposed value-added medicines that have the potential to offer significant advantages over available alternatives. Two products are currently commercialised with partners: Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid post-operative pain treatment. The Company’s development strategy primarily focuses on the FDA’s 505(b)2 regulatory pathway, which is specifically designed for pharmaceuticals for which safety and efficacy of the molecule have already been established. This pathway can reduce the clinical burden required to bring a product to market, and significantly shorten the development timelines and reduce costs and risks. Hyloris is based in Liège, Belgium. For more information, visit www.hyloris.com and follow-us on LinkedIn.
For more information, please contact Hyloris Pharmaceuticals:
Marieke Vermeersch
VP Investor Relations and Corporate Communications
M: +32 (0)479 490 603
marieke.vermeersch@hyloris.com
Disclaimer and forward-looking statements
Hyloris means “high yield, lower risk”, which relates to the 505(b)(2) regulatory pathway for product approval on which the Issuer focuses, but in no way relates or applies to an investment in the Shares.
Certain statements in this press release are “forward-looking statements.” These forward-looking statements can be identified using forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. These statements relate to future events or the Company’s future financial performance and involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company’s control, that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Company announcement no 9/2024 Annual account 202326.4.2024 11:07:04 CEST | Press release
Annual account 2023 Please find enclosed the full annual account for Idavang A/S in zip No changes in financial figures compared to Q4 report published end February Attachments IDAVANG-2023-12-31-enIdavang Annual Report 2023
Åsa Vilsson ny CFO på Elanders26.4.2024 11:00:00 CEST | Pressemelding
Åsa Vilsson har utsetts till ny CFO på Elanders. Hon kommer närmast från rollen som koncernredovisningsansvarig på Elanders och har sedan februari 2024 varit tillförordnad CFO. Åsa tillträder sin roll som CFO och medlem av Elanders koncernledning idag 26 april 2024. Åsa har en bred redovisningsbakgrund och en ekonomie magisterexamen vid Internationella Handelshögskolan i Jönköping. Jag är väldigt glad över att Åsa valt att tacka ja till rollen som CFO och att vi kan tillsätta en så viktig funktion internt, säger Magnus Nilsson, VD och koncernchef. Åsa Vilsson efterträder Andréas Wikner som lämnar Elanders på grund av familjeskäl. Andréas tillträdde rollen som CFO under 2010 och har sedan dess haft en betydande roll i utvecklingen av Elanders. Andréas har bidragit med sin gedigna kompetens och har varit en enorm tillgång för bolaget. Andréas har varit en mycket uppskattad kollega och jag vill framföra ett stort tack till Andréas för det viktiga arbete han utfört under sina år på Elander
Åsa Vilsson new CFO at Elanders26.4.2024 11:00:00 CEST | Press release
Åsa Vilsson has been appointed as the new CFO of Elanders. She most recently served as Vice President of Group Finance at Elanders and has been acting CFO since February 2024. Åsa will enter the role as CFO and member of Elanders’ Group Management today, April 26, 2024. Åsa has a broad background in accounting and a master’s degree in business and economics from Jönköping International Business School. I am very pleased that Åsa has chosen to accept the role as CFO and that we can fill such an important function internally, says Magnus Nilsson, President and CEO. Åsa Vilsson succeeds Andréas Wikner, who is leaving Elanders due to family reasons. Andréas assumed the role of CFO in 2010 and has since had a significant role in the development of Elanders. Andréas has contributed with his solid expertise and has been a huge asset to the company. Andréas has been a much appreciated colleague and I would like to express my sincere thanks to Andréas for the important work he has done during h
Meddelelse nr. 08/2024: Forløb af ordinær generalforsamling26.4.2024 10:57:16 CEST | pressemeddelelse
Strategic Investments A/S (CVR nr. 71064719) afholdte fredag d. 26. april 2024 kl. 10:00 ordinær generalforsamling. Indkaldelse, dagsorden og de fuldstændige forslag fremgår af selskabsmeddelelse nr. 06/2024 af d. 4. april 2024. Bestyrelsen havde udpeget advokat Jens Ahrendt, Mazanti-Andersen Advokatpartnerselskab som dirigent. Dirigenten konstaterede, at generalforsamlingen var rettidigt varslet og beslutningsdygtig. Dagsordenspunkt 1-3 Adm. dir. Jens Black gennemgik årets væsentligste begivenheder, redegjorde for selskabets resultatudvikling i 2023 og gennemgik selskabets balance. Forud for generalforsamlingen havde selskabet offentliggjort delårsrapport for 1. kvartal 2024. Jens Black opsummerede kort udviklingen i 1. kvartal 2024 herunder kvartalets resultat og afkast i hovedtal. Med henvisning til årsrapporten indstillede bestyrelsen til generalforsamlingen, at der, i lighed med for 2022, udloddes udbytte for regnskabsåret 2023 på DKK 0,02 pr. aktie. Beretningen blev taget ti
Development of the Extraordinary General Meeting on Friday 26 April 202426.4.2024 10:47:27 CEST | Press release
ANNOUNCEMENT A.P. Møller - Mærsk A/S - Development of the Extraordinary General Meeting on Friday 26 April 2024 The Extraordinary General Meeting of A.P. Møller - Mærsk A/S took place on Friday 26 April 2024 as a completely electronic general meeting in accordance with the below agenda. The Board of Directors had appointed Niels Kornerup, attorney-at-law, as chair of the meeting. Agenda Completion of the demerger. The General Meeting adopted the Board’s proposal to complete the demerger of A.P. Møller - Mærsk A/S as described in the demerger plan of 22 March 2024 by transfer of the Company’s towage and marine services activities to a new company, Svitzer Group A/S (Svitzer Group) which will be established as part of the demerger. Election of the Board of Directors of Svitzer Group. Morten H. Engelstoft, Robert M. Uggla, Christine Brennet Morris and Peter Wikström were elected as members of the Board of Directors of Svitzer Group until the first annual general meeting of Svitzer Group t